A. Aurange

Interpretable biomarker programs predict treatment response in lupus nephritis: patient-level validation across four regimens

A large share of late-stage clinical trial failures reflects not the underlying biology of the target but the composition of the enrolled population: trials recruit patients in whom the drug cannot work. Methods that identify likely responders before treatment therefore address a failure mode that better target selecti...